Skip to main content

Advertisement

SpringerLink
Log in

Evidence for metabolic abnormalities in the muscles of patients with fibromyalgia

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Widespread muscle pain, fatigue, and weakness are defining characteristics of patients with fibromyalgia (FM). The aim of this review is to summarize recent investigations of muscle abnormalities in FM, which can be classified as structural, metabolic, or functional in nature. Histologic muscle abnormalities of membranes, mitochondria, and fiber type have been well described at both the light microscopic and ultrastructural levels. These structural abnormalities often correlate with biochemical abnormalities, defective energy production, and the resultant dysfunction of FM muscles. The observed abnormalities in FM muscles are consistent with neurologic findings and disturbances in the hypothalamic-pituitary-adrenal axis. Functional changes in FM muscles are assessed most directly by strength and endurance measurements, but pain and psychologic factors may interfere with accurate assessments. To compensate for diminished effort, the decreased efficiency of the work performance by patients with FM can be verified from P-31 magnetic resonance spectroscopy (MRS) data by calculation of the work/energy-cost ratio for various tasks. In the disease course, muscle abnormalities may be elicited by intrinsic changes within the muscle tissue itself and/or extrinsic neurologic and endocrine factors. The accurate assignment of intrinsic or extrinsic factors has been substantially clarified by a recent surge of experimental findings. Irrespective of the multifaceted causes of muscle dysfunction and pain, an in-depth understanding of the muscle defects may provide ideas for characterization of the underlying pathogenesis and development of new therapeutic approaches for fibromyalgia syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Olsen NJ, Park JH: Skeletal muscle abnormalities in patients with fibromyalgia. Am J Med Sci 1998, 351:315–358.This article reviews the histologic, metabolic, and functional abnormalities in FM muscles.

    Google Scholar 

  2. Norregaard J: Muscle function, psychometric scoring and prognosis in patients with widespread pain and tenderness (fibromyalgia). Dan Med Bull 1998, 45:256–267.This article reviews the histologic, metabolic, and functional abnormalities in FM muscles.

    PubMed  CAS  Google Scholar 

  3. Henriksson J: Muscle activity and chronic muscle pain. J Musculoskeletal Pain 1999, 7:101–109.This article reviews the histologic, metabolic, and functional abnormalities in FM muscles.

    Article  Google Scholar 

  4. Russell IJ: Advances in fibromyalgia: possible role for central neurochemicals. Am J Med Sci 1998, 315:377–384.

    Article  PubMed  CAS  Google Scholar 

  5. Giovengo SL, Russell IJ, Larson AA: Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol 1999, 26:1564–1569.This paper details the most recent factor known to increase in the CSF.

    PubMed  CAS  Google Scholar 

  6. Crofford LJ, Demitrack MA: Evidence that abnormalities of central neurohormonal systems are key to understanding fibromyalgia and chronic fatigue syndrome. Rheum Dis Clin NA 1996, 22:267–284.This article presents an excellent summary of the endocrine factors involved in FMS.

    Article  CAS  Google Scholar 

  7. Crofford LJ, Engleberg NC, Demitrack MA: Neurohormonal perturbations in fibromyalgia. Bailliére’s Clin Rheumatol 1996, 10:365–378.

    Article  CAS  Google Scholar 

  8. Bennett RM, Clark SC, Walczyk J: A randomized, doubleblind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med 1998, 104:227–231.These studies detail the effects of deficiency of insulin-like growth factor-1 in some patients with FM and the improvements of clinical status by administration of growth hormone.

    Article  PubMed  CAS  Google Scholar 

  9. Bennett RM, Cook DM, Clark SR, et al.: Hypothalamic-pituitary-insulin-like growth factor-1 axis dysfunction in patients with fibromyalgia. J Rheumatol 1997, 24:1384–1389.These studies detail the effects of deficiency of insulin-like growth factor-1 in some patients with FM and the improvements of clinical statusby administration of growth hormone.

    PubMed  CAS  Google Scholar 

  10. Reidel H, Layka H, Neeck G: Secretory pattern of GSH, TSH, thyroid hormones, ACTH, cortisol, FSH, and LH in patients with fibromyalgia syndrome following systemic injection of the relevant hypothalamic-releasing hormones. Z Rheumatol 1998, 57(suppl 2):81–87.

    Article  Google Scholar 

  11. Henriksson KG, Bengtsson A, Larsson J, et al.: Muscle biopsy findings of possible diagnostic importance in primary fibromyalgia (fibrositis, myofascial syndrome). Lancet 1982, 1:1395.

    Article  Google Scholar 

  12. Yunus MB, Kalyan-Raman UP, Masi AT, Aldag JC: Electron microscopic studies of muscle biopsy in primary fibromyalgia syndrome: a controlled and blinded study. J Rheumatol 1989, 16:97–101.

    PubMed  CAS  Google Scholar 

  13. Bartels EM, Danneskiold-Samsoe B: Histological abnormalities in muscle from patients with certain types of fibrositis. Lancet 1986, 1:755–757.

    Article  PubMed  CAS  Google Scholar 

  14. Jacobsen S, Bartels EM, Danneskiold-Samsoe B: Single cell morphology of muscle in patients with chronic muscle pain. Scand J Rheumatol 1991, 20:336–343.

    PubMed  CAS  Google Scholar 

  15. Drewes AM, Andreasen A, Schroder HD, et al.: Pathology of skeletal muscle in fibromyalgia: a histo-immuno-chemical and ultrastructural study. Brit J Rheumatol 1993, 32:479–483.

    Article  CAS  Google Scholar 

  16. Lindman R, Hagberg M, Bengtsson A, et al.: Changes in trapezius muscle structure in fibromyalgia and chronic trapezius myalgia. In Musculoskeletal Pain, Myofascial Pain Syndrome and the Fibromyalgia Syndrome. Edited by Jacobsen S, Danneskiold-Samsoe B, Lund B. New York: The Haworth Medical Press;1993:171–176.

    Google Scholar 

  17. Lindh MH, Johansson LG, Hedberg M, et al.: Muscle fiber characteristics, capillaries and enzymes in patients with fibromyalgia and controls. Scand J Rheumatol 1995, 24:34–37.

    PubMed  CAS  Google Scholar 

  18. Bengtsson A, Henriksson KG: The muscle in fibromyalgia: a review of Swedish studies. J Rheumatol 1989, 16:144–149.

    Google Scholar 

  19. Pongrantz DE, Späth M: Morphologic aspects of fibromyalgia. Z Rheumatol 1998, 57(suppl 2):47–51.

    Article  Google Scholar 

  20. Sprott H, Bradley LA, Oh SJ, Wintersberger W, et al.: Immunohistochemical and molecular studies of serotonin, substance P, galanin, pituitary adenylyl cyclase-activating polypeptide, and secretoneurin in fibromyalgic muscle tissue. Arthritis Rheum 1998, 41:1689–1694.

    Article  PubMed  CAS  Google Scholar 

  21. Mengshoel AM, Forre O, Komnaes HB: Muscle strength and aerobic capacity in primary fibromyalgia. Clin Exp Rheumatol 1990, 8:475–479.

    PubMed  CAS  Google Scholar 

  22. Nordenskiold UM, Grimby G: Grip force in patients with rheumatoid arthritis and fibromyalgia and in normal subjects. A study with Grippit instrument. Scand J Rheumatol 1993, 22:14–19.

    PubMed  CAS  Google Scholar 

  23. Bengtsson A, Henriksson KG, Jorfeldt L, et al.: Primary fibromyalgia: a clinical and laboratory study of 55 patients. Scand J Rheumatol 1986, 15:340–347.

    PubMed  CAS  Google Scholar 

  24. Jacobsen S, Danneskiold-Samsoe B: Isometric and isokinetic muscle strength in patients with fibrositis syndrome: new characteristics for a difficult definable category of patients. Scand J Rheumatol 1987, 21:28–34.

    Google Scholar 

  25. Park JH, Phothimat P, Oates CT, et al.: Use of P-31 magnetic resonance spectroscopy to detect metabolic abnormalities in muscles of patients with fibromyalgia. Arthritis Rheum 1998, 41:406–413.A quantitative study using P-31 MRS to detect low levels of ATP and phosphocreatine, decreased phosphorylation potential, and oxidative capacity in FM muscles.

    Article  PubMed  CAS  Google Scholar 

  26. Jacobsen S, Wildschiodtz G, Danneskiold-Samsoe B: Isokinetic and isometric muscle strength combined with transcutaneous electrical stimulation in primary fibromyalgia syndrome. J Rheumatol 1992, 18:1390–1393.

    Google Scholar 

  27. Lindh MH, Johansson LG, Hedberg M, Grimby GL: Studies on maximal voluntary contraction in patients with fibromyalgia. Arch Phys Med Rehabil 1994, 75:1217–1222.

    Article  PubMed  CAS  Google Scholar 

  28. Elert J, Rantapaa-Dahlqvist SR, Henriksson-Larsen K, Gerdle BU: Muscle performance, electromyography, and fibre type composition in fibromyalgia and work-related myalgia. Scand J Rheumatol 1991, 21:28–34.

    Google Scholar 

  29. Simms RW, Roy SH, Hrovat M, et al.: Lack of association between fibromyalgia syndrome and abnormalities in muscle energy metabolism. Arthritis Rheum 1994, 37:794–800.

    Article  PubMed  CAS  Google Scholar 

  30. Bennett RM, Clark SR, Goldberg L, et al.: Aerobic fitness in patients with fibrositis: a controlled study of respiratory gas exchange and 133xenon clearance from exercising muscle. Arthritis Rheum 1989, 32:454–460.

    Article  PubMed  CAS  Google Scholar 

  31. Norregaard J, Bulow PM, Vestergaard-Poulsen P, et al.: Muscle strength, voluntary activation and cross-sectional muscle area in patients with fibromyalgia. Br J Rheumatol 1995, 34:925–931.

    Article  PubMed  CAS  Google Scholar 

  32. Vestergaard-Poulsen P, Thomsen C, Norregaard J, et al.: 31P NMR spectroscopy and electromyography during exercise and recovery in patients with fibromyalgia. J Rheumatol 1995, 22:1544–1551.

    PubMed  CAS  Google Scholar 

  33. McCain GA, Bell DA, Mai FM, Halliday PD: A controlled study of the effects of a supervised cardiovascular fitness training program on the manifestations of primary fibromyalgia. Arthritis Rheum 1988, 31:1135–1141.

    Article  PubMed  CAS  Google Scholar 

  34. McCain GA: A clinical overview of the fibromyalgia syndrome. J Musculoskel Pain 1996, 4:9–34.

    Article  Google Scholar 

  35. Mengshoel AM, Komnaes HB, Forre O: The effects of 20 weeks of physical fitness training in female patients with fibromyalgia. Clin Exp Rheumatol 1992, 10:345–349.

    PubMed  CAS  Google Scholar 

  36. Mengshoel AM, Forseth KO, Haugen M, et al.: Multidisciplinary approach to fibromyalgia: a pilot study. Clin Rheumatol 1995, 14:165–170.

    Article  PubMed  CAS  Google Scholar 

  37. Chance B, Younkin DP, Kelly R, et al.: Magnetic resonance spectroscopy of normal and diseased muscles. Am J Med Genetics 1986, 25:659–679.

    Article  CAS  Google Scholar 

  38. Park JH, Vital T, Ryder N, et al.: MR imaging and P-31 MR spectroscopy provide unique quantitative data for longitudinal management of patients with dermatomyositis. Arthritis Rheum 1994, 37:736–746.

    Article  PubMed  CAS  Google Scholar 

  39. Park JH, Olsen NJ: Skeletal muscle imaging for evaluation of myopathy. In Diseases of Skeletal Muscle. Edited byWortmann RL. Philadelphia: Lippincott Williams and Wilkins;2000:293–312.

    Google Scholar 

  40. Bengtsson A, Henriksson KG, Larsson J: Reduced high-energy phosphate levels in the painful muscles of patients with primary fibromyalgia. Arthritis Rheum 1986, 29:817–821.

    Article  PubMed  CAS  Google Scholar 

  41. Russell IJ, Vipraio GA: Red cell nucleotide abnormalities in fibromyalgia syndrome (abstract). Arthritis Rheum 1993, 36:S223.

    Article  Google Scholar 

  42. Eisinger J, Plantamura A, Ayavou T: Glycolysis abnormalities in fibromyalgia. J Am Coll Nutr 1994, 13:144–148.

    PubMed  CAS  Google Scholar 

  43. Chance B, Leigh JS, Maris J, et al.: Control of oxidative metabolism and oxygen delivery in human skeletal muscle: a steady-state analysis of the work/energy cost transfer function. Proc Natl Acad Sci USA 1985, 82:8384–8388.

    Article  PubMed  CAS  Google Scholar 

  44. Kari S, Park JH, Hernanz-Schulman M, Olsen NJ: Analysis of P-31 magnetic resonance spectroscopy data using artificial neural networks for evaluation of fibromyalgia patients (abstract). Arthritis Rheum 1997, 40:S188.

    Article  Google Scholar 

  45. Kari S, Olsen NJ, Park JH: Evaluation of muscle diseases using artificial neural network analysis of 31P MR spectroscopy data. Magnetic Reson Med 1995, 34:664–672.

    Article  CAS  Google Scholar 

  46. Park JH, Kari S, King LE, Olsen NJ: Analysis of P-31 MR spectroscopy data using artificial neural networks for longitudinal evaluation of muscle diseases: dermatomyositis. NMR in Biomedicine 1998, 11:245–265.

    Article  PubMed  CAS  Google Scholar 

  47. de Blecourt AC, Wolf RF, van Rijswijk MH, et al.: In vivo 31P magnetic resonance spectroscopy of tender points in patients with primary fibromyalgia syndrome. Rheumatol Int 1991, 11:51–54.

    Article  PubMed  Google Scholar 

  48. Jacobsen S, Jensen KE, Thomsen C, et al.: 31P magnetic resonance spectroscopy of skeletal muscle in patients with fibromyalgia. J Rheumatol 1992, 19:1600–1603.

    PubMed  CAS  Google Scholar 

  49. Roy SH: Combined use of surface electromyography and 31P-NMR spectroscopy for the study of muscle disorders. Phys Ther 1993, 73:892–901.

    PubMed  CAS  Google Scholar 

  50. Jubrias SA, Bennett RM, Klug GA: Increased incidence of a resonance in the phosphodiester region of 31P nuclear magnetic resonance spectra in the skeletal muscle of fibromyalgia patients. Arthritis Rheum 1994, 37:801–807.

    Article  PubMed  CAS  Google Scholar 

  51. Simms RW, Hrovat M: Role of phosphodiesters (PDE) in muscles of patients with fibromyalgia. Arthritis Rheum 1995, 38:S229.

    Article  Google Scholar 

  52. Eisinger J, Blairet D, Brue F, Ayavou T: Brief clinical note: absence of correlation between magnesium and riboflavin status. Magnes Res 1993, 6:161–162.

    Google Scholar 

  53. Abraham GE, Flechas JD: Managements of fibromyalgia: rationale for use of magnesium and malic acid. J Nutr Med 1992, 3:49–59.

    Google Scholar 

  54. Niermann KJ, Park JH, Olsen NJ: Abnormalities in the levels of total and ATP-bound magnesium (Mg2+) in muscles of fibromyalgia patients. Arthritis Rheum 1998, 41:S1336.

    Google Scholar 

  55. Park JH, Niermann KJ, Carr BN, Olsen NJ: Abnormalities in magnesium (Mg2+) and ATP levels in muscle disorders: dermatomyositis and fibromyalgia. Int Soc Magnetic Resonance Med 1999, 7:1537.

    Google Scholar 

  56. Clauw D, Ward K, Katz P, Sunder R: Muscle intracellular magnesium levels correlate with pain tolerance in fibromyalgia (FM). Arthritis Rheum 1994, 37:S213.

    Article  Google Scholar 

  57. Russell IJ, Michalek JE, Flechas JD, Abraham GE: Treatment of fibromyalgia syndrome with Super Malic(r): a randomized, double blind, placebo controlled, crossover pilot study. J Rheum 1995, 22:953–958.This study represents a promising therapy using magnesium (Super Malic®) for the treatment of FMS.

    PubMed  CAS  Google Scholar 

  58. Lund N, Bengtsson A, Thorborg P: Muscle tissue oxygen pressure in primary fibromyalgia. Scand J Rheum 1986, 15:165–173.

    PubMed  CAS  Google Scholar 

  59. Bengtsson A, Bengtsson M: Regional sympathetic blockade in primary fibromyalgia. Pain 1988, 33:161–167.

    Article  PubMed  CAS  Google Scholar 

  60. Larsson SE, Ålund M, Cai H, Öberg PÅ: Chronic pain after soft-tissue injury of the cervical spine: trapezius muscle blood flow and electromyography at static loads and fatigue. Pain 1994, 57:173–180.

    Article  PubMed  CAS  Google Scholar 

  61. Lindman R, Hagberg M, Bengtsson A, et al.: Capillary structure and mitochondrial volume density in the trapezius muscle of chronic trapezius myalgia, fibromyalgia and healthy subjects. J Musculoskel Pain 1995, 3(3):5–22.

    Article  Google Scholar 

  62. Lindh M, Johansson G, Hedberg M, et al.: Muscle fiber characteristics, capillaries and enzymes in patients with fibromyalgia and controls. Scand J Rheumatol 1995, 24:34–37.

    PubMed  CAS  Google Scholar 

  63. Strobel ES, Krapf M, Suckfull M, et al.: Tissue oxygen measurement and 31P magnetic resonance spectroscopy in patients with muscle tension and fibromyalgia. Rheumatol Int 1997, 16:175–180.

    Article  PubMed  CAS  Google Scholar 

  64. Bank W, Chance B: An oxidative defect in metabolic myopathies: diagnosis by noninvasive tissue oximetry. Annals Neurology 1994, 36:830–837.

    Article  CAS  Google Scholar 

  65. Park JH, Olsen NJ, Lech G, et al.: Paradoxical oxygenation of muscle during exercise by patients with dermatomyositis as detected by near infrared spectroscopy. Arthritis Rheum 1995, 38:S168.

    Article  Google Scholar 

  66. Marin R, Connick E: Tension myalgia versus myoadenylate deaminase deficiency: a case report. Arch Phys Med Rehabil 1997, 78:95–97.

    Article  PubMed  CAS  Google Scholar 

  67. Wortmann RL: Searching for the cause of fibromyalgia: is there a defect in energy metabolism? Arthritis Rheum 1994, 37:790–793.

    Article  PubMed  CAS  Google Scholar 

  68. Wortmann RL: Metabolic diseases of muscle.In In Diseases of Skeletal Muscle. Edited by Wortmann RL. Philadelphia:Lippincott Williams and Wilkins; 2000:157–188.An excellent new book on the metabolic diseases of muscle.

    Google Scholar 

  69. Gotze FR, Thid S, Kyllerman M: Fibromyalgia in hyperkalemic periodic paralysis. Scand J Rheumatol 1998, 27:383–384.

    Article  PubMed  CAS  Google Scholar 

  70. Travell JG, Simons DG: Myofascial pain and dysfunction: the trigger point manual. Baltimore: Williams and Wilkins; 1983.

    Google Scholar 

  71. Bengtsson M, Bengtsson A, Jorfeldt L: Diagnostic epidural opioid blockade in primary fibromyalgia at rest and during exercise. Pain 1989, 39:171–180.

    Article  PubMed  CAS  Google Scholar 

  72. Bennett RM: The contribution of muscle to the generation of muscle symptomatology. J Musculoskeletal Pain 1996, 4:35–59.An excellent review of muscle abnormalities which contribute to the clinical symptomatology of FM.

    Article  Google Scholar 

  73. Arroyo JF, Cohen ML: Abnormal responses to electrocutaneous stimulation in fibromyalgia. J Rheumatol 1993, 20:1925–1931.

    PubMed  CAS  Google Scholar 

  74. Dickenson AH, Sullivan AF: NMDA receptors and central hyperalgesic states. Pain 1991, 46:344–346.

    Article  PubMed  CAS  Google Scholar 

  75. Dougherty PM, Willis WD: Enhancement of spinothalamic neuron responses to chemical and mechanical stimuli following combined micro-iontophoretic application of Nmethyl-D-aspartic acid and substance P. Pain 1992, 47:85–93.

    Article  Google Scholar 

  76. Sorenson J, Bengtsson A, Backman E, et al.: Pain analysis in patients with fibromyalgia: effects of intravenous morphine, lidocaine and ketamine. Scand J Rheumatol 1995, 24:360–365.Therapeutic treatments based on the knowledge of neurochemical defects in FMS.

    Google Scholar 

  77. Russell IJ, Orr MD, Littman B, et al.: Elevated cerebrospinal levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994, 37:1593–1601.

    Article  PubMed  CAS  Google Scholar 

  78. Russell IJ: Neurochemical pathogenesis of fibromyalgia. Z Rheumatol 1998, 57(suppl 2:,63–66.

    Article  PubMed  Google Scholar 

  79. Crofford LJ, Pillemer SR, Kalogeras KT, et al.: Hypothalamicpituitary-adrenal perturbations in patients with fibromyalgia. Arthritis Rheum 1994, 37:1583–1592.

    Article  PubMed  CAS  Google Scholar 

  80. Bennett RM: Emerging concepts in the neurobiology of chronic pain: evidence of abnormal sensory processing in fibromyalgia. Mayo Clinic Proc 1999, 74:385–398.A critical review of the neurobiology of chronic pain, with special emphasis on fibromyalgia.

    Article  CAS  Google Scholar 

  81. McCain GA: Treatment of fibromyalgia syndrome. J Musculoskeletal Pain 1999, 7:193–208.A comprehensive summary of current therapies for fibromyalgiacdocumented with data from well-controlled blinded studies.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Vanderbilt University School of Medicine, Department of Radiology, Division of Rheumatology and Immunology, Department of Medicine, Vanderbilt University, 3219 Medical Center North, 37232-2681, Nashville, TN, USA

    Jane H. Park PhD, Kenneth J. Niermann & Nancy J. Olsen MD

Authors
  1. Jane H. Park PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenneth J. Niermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nancy J. Olsen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Park, J.H., Niermann, K.J. & Olsen, N.J. Evidence for metabolic abnormalities in the muscles of patients with fibromyalgia. Curr Rheumatol Rep 2, 131–140 (2000). https://doi.org/10.1007/s11926-000-0053-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-000-0053-3

Keywords

Search

Navigation